NICE’s interim second draft guidance does not recommend lecanemab for use within the NHS in England and Wales at this time.

Octapharma has announced that, for the first time in almost 30 years, NHS patients are receiving medicines made from ...

The Safety Review Committee (SRC) has confirmed the end of the Dose Escalation phase and the start of the cohort expansion ...

To reduce waiting lists and enhance patient communication, Rotherham NHS Foundation Trust has adopted Netcall’s Liberty for ...

Kenvue has appointed Bas Vorsteveld as Area Managing Director for Northern Europe. He will oversee Kenvue’s business in the ...

Centauri Therapeutics Limited has announced the selection of its first clinical candidate for the ABX-01 programme. The ...

Kenvue has appointed Bas Vorsteveld as Area Managing Director for Northern Europe. He will oversee Kenvue’s business in the UK, Ireland, Norway, Sweden, Denmark and Finland. Bas will manage a ...

Grünenthal has announced that Professor Dr Uli Brödl will assume the role of Chief Scientific Officer (CSO) and Member of the ...

Research from the Blood Cancer Alliance reveals a significant disparity in access to new blood cancer treatments on the NHS.

Entering the post-approval phase marks a critical pivot for pharmaceutical companies, shifting their focus from the ...